12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Trabedersen: Phase II start

Next half, Antisense will begin a 2-stage Phase II trial to evaluate systemic IV trabedersen in patients with malignant melanoma, pancreatic cancer and other tumors. The first stage includes a dose-confirmatory component, while the second stage will compare trabedersen vs. standard chemotherapy for 1-2 "key" tumor indications...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >